Effect of sirolimus on immune reconstitution following myeloablative allogeneic stemcell transplantation: An ancillary analysis of a randomized controlled trial comparing Tacrolimus/Sirolimus with Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402)

INTRODUCTION: Although allogeneic hematopoietic cell transplantation (HCT) is a potentially curative therapy for hematologic neoplasms, one of its limiting toxicities continues to be graft versus host disease, both acute and chronic (aGVHD, cGVHD). Sirolimus is a mammalian target of rapamycin (mTOR)...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Biol Blood Marrow Transplant
Main Authors: Gooptu, Mahasweta, Kim, Haesook T., Howard, Alan, Choi, Sung W., Soiffer, Robert J., Antin, Joseph H., Ritz, Jerome, Cutler, Corey S.
Format: Artigo
Jezik:Inglês
Izdano: 2019
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7304072/
https://ncbi.nlm.nih.gov/pubmed/31271885
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2019.06.029
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki